Anita Dushyanth

Jeff Cohen

Jeffrey Cohen

- SINTX Technologies announced a **Notice of Allowance** from the USPTO for a U.S. patent application covering method claims for its **antipathogenic fabric technology**, complementing a previously issued composition patent (U.S. Patent No. 12,433,356 granted on **October 7, 2025**).  **[1269026_ef560e27cbda40798e044f7296aede79_0]** 
- This dual patent coverage significantly **strengthens the company's intellectual property** and competitive advantage, enabling broader licensing and product opportunities across medical textiles, filtration media, and other infection-prone surfaces.  **[1269026_ef560e27cbda40798e044f7296aede79_0]** 
- The technology addresses an accessible market estimated at approximately **$30 billion** across medical textiles, wound management, filtration/PPE, and healthcare infrastructure.  **[1269026_ef560e27cbda40798e044f7296aede79_1]** 
- SINTX plans to pursue **licensing and co-development partnerships** to commercialize its silicon nitride technology platform, leveraging the dual-patent estate for flexible deal structures.  **[1269026_ef560e27cbda40798e044f7296aede79_0]** **[1269026_ef560e27cbda40798e044f7296aede79_1]**

SINTX Technologies Secures New U.S. Patent for Antipathogenic Fabric Technology

- SINTX Technologies announced a **Notice of Allowance** from the USPTO for a new patent application covering **method claims** for its antipathogenic fabric technology.  **[1269026_67c60bd257fe4c67ae7dc31dfab4d430_0]** 
- This new patent expands the company's intellectual property, complementing a previously issued U.S. Patent No. 12,433,356, granted on **October 7, 2025**, which covers the **composition** of silicon nitride for antipathogenic fibrous materials.  **[1269026_67c60bd257fe4c67ae7dc31dfab4d430_0]** 
- This dual patent coverage is expected to enhance **licensing and partnership opportunities** and broaden potential applications across medical textiles, filtration media, and other infection-prone surfaces.  **[1269026_67c60bd257fe4c67ae7dc31dfab4d430_0]** 
- The accessible market for this silicon nitride-based platform is estimated at **~$30 billion** across medical textiles, wound management, filtration/PPE, and healthcare infrastructure.  **[1269026_67c60bd257fe4c67ae7dc31dfab4d430_1]**

SINTX Technologies Strengthens IP with New Antipathogenic Fabric Patent

- SINTX Technologies, Inc. entered into an **At The Market Offering Agreement** with H.C. Wainwright & Co., LLC on **October 3, 2025**, to sell shares of its common stock.  **[1269026_0001493152-25-016904_form8-k.htm:1]** 
- The company may offer and sell up to **$6,413,876** of common stock through this program.  **[1269026_0001493152-25-016904_ex5-1.htm:0]** **[1269026_0001493152-25-016904_form8-k.htm:1]** 
- H.C. Wainwright & Co., LLC will act as the sales agent and receive a **3.0% commission** on the aggregate gross sales price.  **[1269026_0001493152-25-016904_form8-k.htm:1]** 
- SINTX Technologies is not obligated to sell any shares and may suspend the offering at any time.  **[1269026_0001493152-25-016904_form8-k.htm:1]**

SINTX Technologies Enters At The Market Offering Agreement

- SINTX Technologies announced the publication of a peer-reviewed study demonstrating that its silicon nitride material exhibits **potent antiviral activity** against multiple infectious virus strains, including SARS-CoV-2 and MERS-CoV.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_0]** 
- This breakthrough opens doors to a wide range of infection-control applications, such as **wound dressings, surgical sutures, face masks, hospital linens, and HEPA filters**.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_0]** 
- The global infection-prevention and control market is projected to exceed **$230 billion by 2032**, with the antiviral PPE market alone estimated to reach **$40+ billion by 2030**.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_1]** 
- SINTX is uniquely positioned as the **only U.S.-based FDA-cleared and ISO-certified silicon nitride manufacturer** to commercialize this technology.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_1]** 
- The company is strategically transitioning from an orthopedic implant manufacturer to a platform technology company, actively pursuing partnerships and licensing opportunities to accelerate commercialization.  **[1269026_48d082afb3c94f6db868c02ee6b452fc_1]**

Sintx Technologies (SINT)